We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PerkinElmer Gets First FDA Nod for Assay to Detect Spinal Muscular Atrophy in Newborns
PerkinElmer Gets First FDA Nod for Assay to Detect Spinal Muscular Atrophy in Newborns
PerkinElmer has gained FDA marketing authorization for its EONIS assay to simultaneously detect spinal muscular atrophy (SMA) and severe combined immunodeficiency (SCID) in newborns — making it the first assay authorized by the FDA for SMA screening in newborns.